Pharmacotherapy for knee osteoarthritis: current and emerging therapies

被引:93
作者
Cao, Peihua [1 ]
Li, Yamin [1 ]
Tang, Yujin [2 ]
Ding, Changhai [1 ,3 ]
Hunter, David J. [1 ,4 ,5 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Clin Res Ctr, Guangzhou, Guangdong, Peoples R China
[2] Youjiang Med Univ Nationalities, Dept Orthped Surg, Affiliated Hosp, Baise, Guangxi, Peoples R China
[3] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia
[4] Royal North Shore Hosp, Dept Rheumatol, Sydney, NSW, Australia
[5] Univ Sydney, Inst Bone & Joint Res, Kolling Inst, Sydney, NSW, Australia
关键词
Osteoarthritis; disease modification; pain; pharmacotherapy; NERVE GROWTH-FACTOR; TOPICAL DICLOFENAC SODIUM; VITAMIN-D SUPPLEMENTATION; SELECTIVE INOS INHIBITOR; MECHANISM-BASED APPROACH; POST-HOC ANALYSIS; DOUBLE-BLIND; INTRAARTICULAR SPRIFERMIN; CARTILAGE THICKNESS; STRONTIUM RANELATE;
D O I
10.1080/14656566.2020.1732924
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Osteoarthritis (OA) is the leading cause of pain, loss of function and disability in the elderly, with the knee being the most impactful joint affected. Currently, there is still no 'cure' in OA treatment. Areas covered: The authors review the current and emerging therapies for knee OA including traditional OA medications (oral and topical NSAIDs, acetaminophen, and opioids) and emerging treatments including disease-modifying OA drugs. The failures of agents that have been through clinical trials are also summarized. Furthermore, the authors provide their expert perspectives on the future of pharmacotherapy for knee osteoarthritis. Expert opinion: Compared to traditional OA medications, new disease-modifying OA drugs that act by reducing inflammation and increasing cartilage repair show promise to address the unmet need of disease modification. Many of these new drugs, however, are in the preclinical stage. Long-term RCTs are expected to identify the safety and efficacy of novel OA pharmacotherapy medicines.
引用
收藏
页码:797 / 809
页数:13
相关论文
共 124 条
[41]   Osteoarthritis [J].
Hunter, David J. ;
Bierma-Zeinstra, Sita .
LANCET, 2019, 393 (10182) :1745-1759
[42]   Preface [J].
Hunter, David J. .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2014, 28 (01) :1-3
[43]   Association between serum concentration of 25-hydroxyvitamin D and the risk of hip arthroplasty for osteoarthritis: result from a prospective cohort study [J].
Hussain, S. M. ;
Daly, R. M. ;
Wang, Y. ;
Shaw, J. E. ;
Magliano, D. J. ;
Graves, S. ;
Ebeling, P. R. ;
Wluka, Anita ;
Cicuttini, Flavia M. .
OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (12) :2134-2140
[44]  
Järvinen K, 2008, CLIN EXP RHEUMATOL, V26, P275
[45]   Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment [J].
Jeon, Ok Hee ;
Kim, Chaekyu ;
Laberge, Remi-Martin ;
Demaria, Marco ;
Rathod, Sona ;
Vasserot, Alain P. ;
Chung, Jae Wook ;
Kim, Do Hun ;
Poon, Yan ;
David, Nathaniel ;
Baker, Darren J. ;
van Deursen, Jan M. ;
Campisi, Judith ;
Elisseeff, Jennifer H. .
NATURE MEDICINE, 2017, 23 (06) :775-+
[46]   EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) [J].
Jordan, KM ;
Arden, NK ;
Doherty, M ;
Bannwarth, B ;
Bijlsma, JWJ ;
Dieppe, P ;
Gunther, K ;
Hauselmann, H ;
Herrero-Beaumont, G ;
Kaklamanis, P ;
Lohmander, S ;
Leeb, B ;
Lequesne, M ;
Mazieres, B ;
Martin-Mola, E ;
Pavelka, K ;
Pendleton, A ;
Punzi, L ;
Serni, U ;
Swoboda, B ;
Verbruggen, G ;
Zimmerman-Gorska, I ;
Dougados, M .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (12) :1145-1155
[47]   Emerging Pathways and Promising Agents with Possible Disease Modifying Effect in Osteoarthritis Treatment [J].
Jotanovic, Zdravko ;
Mihelic, Radovan ;
Sestan, Branko ;
Dembic, Zlatko .
CURRENT DRUG TARGETS, 2014, 15 (06) :635-661
[48]   Long-Term Effects of Chondroitins 4 and 6 Sulfate on Knee Osteoarthritis The Study on Osteoarthritis Progression Prevention, a Two-Year, Randomized, Double-Blind, Placebo-Controlled Trial [J].
Kahan, Andre ;
Uebelhart, Daniel ;
De Vathaire, Florent ;
Delmas, Pierre D. ;
Reginster, Jean-Yves .
ARTHRITIS AND RHEUMATISM, 2009, 60 (02) :524-533
[49]   Potent inhibitors precise to S1′ loop of MMP-13, a crucial target for osteoarthritis [J].
Kalva, Sukesh ;
Saranyah, K. ;
Suganya, P. Rathi ;
Nisha, M. ;
Saleena, Lilly M. .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2013, 44 :297-310
[50]   Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future [J].
Karsdal, M. A. ;
Michaelis, M. ;
Ladel, C. ;
Siebuhr, A. S. ;
Bihlet, A. R. ;
Andersen, J. R. ;
Guehring, H. ;
Christiansen, C. ;
Bay-Jensen, A. C. ;
Kraus, V. B. .
OSTEOARTHRITIS AND CARTILAGE, 2016, 24 (12) :2013-2021